Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all four ...

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

Ryoncil is an allogeneic mesenchymal stromal cell (MSC) therapy indicated for the treatment of acute graft-versus-host disease (aGvHD) for children older than two months, including adolescents and ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...

Mesoblast stock surged after FDA approval of Ryoncil for SR-aGVHD, but market size is limited with NPV of ~$1B vs $2.33B market cap. Ryoncil faces commercialization challenges: second-line therapy ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

FDA approved Ryoncil® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR ...

Ryoncil® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and ...